Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health, Inc. (symbol: TDOC) is the issuer of record for a Form 4 filing submitted to the SEC.
Teladoc Health, Inc. (TDOC) had a Form 3 filed for Michael F. Grasher, who is identified as the company’s Chief Financial Officer. This represents his initial statement of beneficial ownership as an officer. The filing lists no reportable transactions or derivative positions and references an attached Power of Attorney.
Teladoc Health, Inc. (TDOC) appointed Michael Grasher as Chief Financial Officer, effective August 31, 2026, while Charles Divita III continues as Chief Executive Officer. Grasher brings over three decades of financial and insurance-sector experience, including CFO roles at IFG Companies, Fortegra Group and AMERISAFE, Inc., plus prior equity research experience.
His offer includes a $550,000 base salary, a one-time $500,000 sign-on bonus, an annual bonus target of 85% of base salary beginning in 2027, and a new-hire equity award with a target value of $3,000,000, split 50% restricted stock units and 50% performance stock units tied to 2026 adjusted EBITDA and 2026–2028 revenue CAGR, with multi-year vesting. An employment agreement provides salary, bonus-related amounts, health benefits and equity vesting acceleration upon certain terminations, with enhanced benefits if a qualifying termination occurs within 12 months after a change of control.
Teladoc Health, Inc. reported a planned board change. On August 10, 2026, director David B. Snow, Jr. informed the company of his intention to retire from its Board of Directors, effective September 30, 2026. He has served as a director since 2014.
The company states that Mr. Snow is retiring for personal reasons and that his decision is not due to any disagreement with the company on any matter. Teladoc expressed its appreciation for his dedicated service.
Anquillare Mark V reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. reported that director Mark V. Anquillare received a grant of 37,425 Restricted Stock Units on 2026-08-03, each representing a contingent right to one share of common stock. One-third of the units vest on the first anniversary of the grant, with the remainder vesting in eight substantially equal quarterly installments, leaving him with 37,425 RSUs directly held after the award.
Teladoc Health, Inc. identifies Mark V Anquillare as a reporting person by submitting an initial statement of beneficial ownership on Form 3 in his capacity as a director. The statement lists no equity transactions and includes a remark referencing Exhibit 24 — Power of Attorney.
Teladoc Health, Inc. increased its Board of Directors to ten members and appointed Mark V. Anquillare as an independent director effective August 3, 2026. He joins both the audit and compensation committees and has been designated an “audit committee financial expert” under SEC and New York Stock Exchange rules.
The company states there are no related-party arrangements or transactions requiring disclosure in connection with his appointment. Anquillare will receive the same indemnification protections and be eligible for the standard compensation programs for Teladoc Health’s non‑employee directors. A press release announcing his appointment was issued on August 3, 2026.
Teladoc Health, Inc. reported lower revenue and continued losses for the quarter ended June 30, 2026. Revenue was $606,927 (thousands), down from $631,900 (thousands) a year earlier, as growth in the Integrated Care segment only partly offset declines in BetterHelp revenue and paying users.
Net loss for the quarter increased to $38,908 (thousands), while loss from operations narrowed versus the prior year due to reduced advertising, marketing, and overhead spending. Adjusted EBITDA was $65,713 (thousands), slightly below 2025 levels. BetterHelp Paying Users fell 11% to 0.346 million, and management highlighted ongoing pressure from a shift toward insurance-covered services. In Integrated Care, U.S. members declined about 2% to 100.3 million, but chronic care program enrollment rose 14% to 1.272 million. Cash and cash equivalents were $774,348 (thousands), and the company carries $1,000,000 (thousands) of 1.25% convertible senior notes due 2027, now classified as current. A goodwill impairment test for the BetterHelp reporting unit identified no impairment, though management notes that future performance or share-price changes could trigger additional testing.
Teladoc Health reported Second Quarter 2026 revenue of $606.9 million, down 4% year over year, and a net loss of $38.9 million, or $0.21 per share. Adjusted EBITDA was $65.7 million, a 5% decrease from the prior year, and results were within previously communicated consolidated guidance ranges.
The Integrated Care segment generated revenue of $394.3 million, up 1%, with adjusted EBITDA of $65.2 million and a 16.5% margin, compared with 14.7% a year earlier. U.S. Integrated Care members totaled 100.3 million and chronic care program enrollment rose 14% to 1.272 million. BetterHelp revenue declined 12% to $212.6 million, and adjusted EBITDA fell to $0.5 million, a 0.2% margin, amid weaker cash-pay demand and rapid growth in insurance-covered services.
For the first six months of 2026, revenue declined 3% to $1.22 billion and net loss was $102.7 million, versus $125.7 million in 2025, when results included a $59.1 million non-cash goodwill impairment. Second Quarter 2026 operating cash flow was $64.7 million and free cash flow $35.7 million. For full-year 2026, Teladoc forecasts revenue of $2.362–$2.447 billion, adjusted EBITDA of $271–$303 million, free cash flow of $130–$170 million, and a net loss per share between $1.00 and $0.75.
Teladoc Health, Inc. executive Kelly Bliss, President of U.S. Group Health, sold 2,500 shares of Teladoc common stock in an open-market transaction at $9.50 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. After this sale, she directly holds 84,878 Teladoc shares.